Improved prognosis of generalized AL-amyloidosis ina patient with multiple myeloma treated according to theVAD scheme
- 作者: Sarkisova I1, Rameev V1, Kozlovskaya L1, Andreeva N2
-
隶属关系:
- ММА им. И. М. Сеченова
- Больница МПС № 2, Москва
- 期: 卷 78, 编号 8 (2003)
- 页面: 81-83
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33407
- ID: 33407
如何引用文章
全文:
作者简介
I Sarkisova
ММА им. И. М. СеченоваММА им. И. М. Сеченова
V Rameev
ММА им. И. М. СеченоваММА им. И. М. Сеченова
L Kozlovskaya
ММА им. И. М. СеченоваММА им. И. М. Сеченова
N Andreeva
Больница МПС № 2, МоскваБольница МПС № 2, Москва
参考
- Тареева И. Е. (ред.) Нефрология. Руководство для врачей. М.; 2000.
- Dubrey S. W., Cha К., Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Quart. J. Med. 1998; 91 (2): 141-157.
- Reisinger J., Dubrey S. W., Lavalley M. et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. Am. Coll. Cardiol. 1997; 30 (4): 1046-1051.
- Falk R. H., Plehn J. F., Deering T. et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis.Am. J. Cardiol. 1987; 59 (5): 418-422.
- Dubrey S. W., Bilazarian S., LaVatley M. et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am. Heart J. 1997; 134 (6): 994-1001.
- Falk R. H., Skinner M. The systemic amyloidosis: an overview. Advanc. Intern. Med. 2000; 45: chapt. 4.
- Ropper A., Gorson K. Current concepts: Neuropathies associated with paraproteinemia. N. Engl. J. Med. 1998; 338: 1601- 1607.
- Falk R. H., Comenzo R. L., Skinner M. The systemic amyloidosis. Ibid. 1997; 1: 898-909.
- Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995; 32: 45-59.
- Tada S., lida M., Yao T. et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34 (10): 1412-1417.
- Kitchens C. S. The anatomic basis of purpura. Progr. Hemostas. Thrombos. 1980; 5: 211-244.
- Sezer O., Eucker J., Schmid P., P ossinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann. Hematol. 2000; 79: 1-6.
- Kyle R. A., Greipp P. R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978; 52: 818-827.
- Kyle R. A., Gertz M. A., Greipp P. R. et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.N. Engl. J. Med. 1997; 336: 1202-1207.
- Comenzo R. L., Vosburgh E., Falk R. H. et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91 (10): 3662-3670.
- Van E. K., Zachee P., Maertens J. et. al. Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Ibid. 1996; 88: 591.
- Schena P. P., Pannarale G., Carbonara M. C. Clinical and therapeutic aspects of renal amyloidosis. Nephrol. Dial. Transplant. 1996; 1(9): 63-86.